Company Overview and News
Estee Lauder (NYSE:EL) investors have had a good 2018 so far and I believe EL stock is likely to continue its run up in this last quarter of the year, too. Specifically, there are three bullish plays in EL stock that I want to share with you, as each play could lead to impressive profits.
IPAR HELE EL AVP NUS COTY
Constellation Brands, Inc. (STZ - Free Report) is scheduled to release second-quarter fiscal 2019 results on Oct 4. Notably, this leading wine company missed earnings estimates in the previous quarter after 14 consecutive beats. Nevertheless, it pulled off an average positive earnings surprise of 5.4% in the trailing four quarters.
STZ.B WEED MNST AVP STZ CGC MO
PepsiCo, Inc. (PEP - Free Report) is set to report third-quarter 2018 results on Oct 2, before the market opens. In the last-reported quarter, the company delivered a positive earnings surprise of 6.6%. It also surpassed expectations in each of the trailing four quarters, with an average of 4%. Let’s See How Things are Shaping Up for Q3 PepsiCo has been trying to improve performance through product launches, fortifying developing/emerging market presence, aggressive marketing, productivity improvement and cost-saving initiatives.
PEP MNST AVP MO
2018-09-25 247wallst - 2
Stocks have hit all-time highs, and Monday’s losses were followed with what looked to be a positive open on Tuesday for the major equity indexes. The markets are dealing with trade tariffs and with the Federal Reserve meeting this week. Many investors also have seen lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how to position their investments for the rest of 2018 and as 2019 approaches.
CHKVP AVP CHKDH CHKVZ CENT CLH ABT CNI CHKDG DLTR SIRI CHKDJ HUN CHKDP MS INTC ABX ABT CKRGZ ABX BX MCHP ON CADE CHKWZ NITE WEN HP BJ CZR CHK CHK.WI TRI QCOM TS CLX
The Dow recorded a second straight all-time high on Friday led by a rally in industrials. However, a slump in technology and internet-related stocks weighed on the Nasdaq. The S&P 500 also closed lower on Friday, ahead of Monday’s major sector reshuffle. That said, trading volumes increased to its highest level since Feb 9 in anticipation of the S&P 500 sector change.
CBS FB CBS.A AVP NFLX CBS.WD NDAQ GOOGL BOE TWTR AAPL CPV BA
Shares of Avon Products, Inc. (AVP - Free Report) rose 1.7% after the company announced its long-term financial targets for 2021, backed by a new growth strategy. On its Investor Day, the company updated about the "Open Up Avon" strategy, which is aimed at bringing Avon back on the growth trajectory. This latest strategy mainly focuses on reviving its direct selling business, renovating the brand, enhancing e-commerce and other capabilities to aid a performance-driven transformation.
KBH EL AVP NUS
Avon Products Inc. AVP, +0.82% was upgraded to buy from neutral at D.A. Davidson on confidence in the beauty company's new management team and its growth targets. Analysts raised their price target to $3.50 from $1.75. Avon shares rose 3.7% in Monday premarket trading. D.A. Davidson highlights that Jan Zijderveld, the company's new chief executive, has set an operating margin growth target of at least 10% in 2021.
2018-09-24 247wallst - 3
Stocks have hit all-time highs, but they were indicated marginally lower on Monday after trade tariffs are set to kick in against China. Many investors have seen lower upside from buying on market pullbacks than in prior years, and now they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
WFCNP TXRH EAT APD CCV UAA KRYS AVP DRI CCZ AMD ABT CMCSK ABT WFC AGTC RDC CMCSA NBEV UNFI UA ABRW CZR CCV.CL MU TRI COHU UNH
Avon Products Inc. AVP, +3.96% shares jumped 4.2% in early Friday trading after the beauty company guided for low-single digit revenue growth, low double-digit margins, and $400 million in cost savings by 2021. The announcement is part of Avon's investor day, in which the company said it has a strategy to reboot the company that includes a focus on recruiting and retaining sales talent and refreshing the brand.
Investors in Avon Products, Inc. (AVP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $2.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
Shares of Avon Products, Inc. (AVP - Free Report) rallied 13.9% in after-hours trading on Sep 17. Per sources, the stock gained on rumors related to its potential takeover by Natura & Co — the leading Brazilian manufacturer and direct-seller of beauty and personal care products. However, Natura denies rumors of any such buyout talks with Avon. Earlier, the company had received “expressions of interest” from other parties.
CLXT TXN MDPEB AVP NUS MDP
AutoZone – The autoparts retailer earned an adjusted $18.54 per share for its fiscal fourth quarter, beating the consensus estimate of $17.92 a share. Revenue missed forecasts, however, and a same-store sales increase of 2.2 percent was also slightly below estimates.
GHC NUACF GIS AVP
2018-05-28 - Asif
Business Avon Products is a global manufacturer and marketer of beauty and related products. The company commenced operations in 1886 and were incorporated in the State of New York on January 27, 1916. The company conduct its business in the highly competitive beauty industry and compete against other consumer packaged goods ("CPG") and direct-selling companies to create, manufacture and market beauty and non-beauty-related products. The company's product categories are Beauty and Fashion & Home. Beauty consists of skincare, fragrance and color (cosmetics). Fashion & Home consists of fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products and nutritional products. The company's business is conducted primarily in one channel, direct selling. The company's reportable segments are based on geographic operations in four regions: Europe, Middle East & Africa; South Latin America; N...
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to AVP / Avon Products, Inc. on message board site Silicon Investor.
|Avcorp Industries Inc. AVP-TSE||Avcorp Industries Inc. AVP-TSE||Avcorp Industries Inc. AVP-TSE|
as of ET